Oral renin inhibitors

TL;DR: In this article, el capitulo presenta una introduccion sobre la versatilidad de las enzimas hidroliticas en biotransformaciones and sus principales aplicaciones in la sintesis de farmacos.

TL;DR: In high-risk, overweight/obese patients with hypertension, traditional therapy provides significantly greater BP- versus aliskiren-lowering throughout the 24-hour dosing interval; overall aliskirens-based treatment offers sustained control of PRA.

TL;DR: For the first time in heart failure patients, the benefits of a more specific approach to neurohumoral manipulation using a recently developed renin inhibitor, aliskiren, are reported.

TL;DR: Aliskiren is the first of these new non-peptide direct renin inhibitors to be approved for the treatment of hypertension and is reviewed in relation to those studies that compared clinical efficacy of aliskiren in comparison and in addition to other antihypertensive drug strategies.

TL;DR: In vivo recent evidence suggest that the activation of mitogen-activated protein kinases and activator protein-1 by Ang II may play the key role in cardiovascular and renal diseases, however, there are still unresolved questions and controversies on the mechanism of Ang II-mediated cardiovascular and kidneys diseases.

TL;DR: The benefits of ACE inhibitors or ARBs on renal outcomes in placebo-controlled trials probably result from a blood-pressure-lowering effect, and in patients with diabetes, additional renoprotective actions of these substances beyond lowering blood pressure remain unproven.

TL;DR: Although the differences between patients in remission and healthy controls did not reach statistical significance, there were substantial rises in bradykinin during acute attacks of hereditary, acquired, or captopril-induced angio-oedema.

TL;DR: Once-daily oral treatment with aliskiren lowers blood pressure effectively, with a safety and tolerability profile comparable to that of irbesartan and placebo, in patients with mild-to-moderate hypertension.